M1231 (EGFR/MUC1 bispecific ADC)
Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Phase 1Active
Key Facts
Indication
Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma
Phase
Phase 1
Status
Active
Company
About Sutro Biopharma
Sutro Biopharma is advancing a differentiated ADC platform and pipeline with the goal of redefining cancer therapy. Its core XpressCF® technology enables the cell-free synthesis and site-specific conjugation of proteins, allowing for the creation of homogeneous ADCs with optimized properties. The company's strategy combines internal development of lead assets, like luveltamab tazevibulin, with strategic platform partnerships to validate its technology. Despite a challenging market valuation, Sutro's clinical progress and platform capabilities position it as a unique player in the competitive ADC landscape.
View full company profile